Utah Peaks Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Utah Peaks Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,500	Closed	-$419K	–	15
2023 Q1	$419K	Buy	+5,500	New	+$456K	0.56%	23

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Utah Peaks Capital's XBI Position: Q2 2023 in Review

Utah Peaks Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 5,500 shares — an estimated $419K sold.

Utah Peaks Capital first reported a position in XBI in Q1 2023 and held it in 1 quarter. The position peaked at $419K in Q1 2023. 713 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

Utah Peaks Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
Utah Peaks Capital sold 5,500 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $419K.
Utah Peaks Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and held it in 1 quarter.
Utah Peaks Capital's State Street SPDR S&P Biotech ETF position peaked at $419K in Q1 2023.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on Utah Peaks Capital's 13F filing for Q2 2023.